AL is an efficacious drug for the treatment of uncomplicated falciparum malaria.
The introduction of mRDTs is likely to be considered cost-effective in this high transmission setting as this intervention increased the number of appropriately treated children at low cost.
Although treatment is highly efficacious, selection of molecular markers in reinfections could indicate a decreased sensitivity or tolerance of parasites to the current treatments and the baseline prevalence of molecular markers should be closely monitored.
The produced maps show great variations in parasitaemia risk across the country and identify the districts where interventions are being effective.
There is no clear cut trajectory for management of uncomplicated malaria in the study area. Different approaches are adopted when treating malaria.
Overall, ACT knowledge among frontline health care providers is very poor.
This study confirms that both AL and ASAQ remain highly efficacious and well tolerated for the treatment of uncomplicated malaria in Mozambican children.
These factors determine the adherence to the dosing schedules during the treatment course and thus the evaluation of the subsidy policy, its implementation and role in malaria burden in this region is compulsory.
